ERC Starting Grant · 2024
Small molecule anti-cancerSmall molecule anti-cancer therapies generally have a well understood mechanism of action. Still, they are frequently plagued by poor efficacy and high rates of treatment resistance, especially in the context of pancreatic cancer. One promising newly recognised route of therapy resistance is intratumoral drug inactivation through members of the tumour microenvironment (TME) such as the tumour-associated microbiome. With the CITE project, I aim to develop novel analytical technologies that enable us to study drug metabolism by the TME in situ and in isolation from systemic drug metabolism and provide a novel platform for selectively studying the contribution of the…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.